- Home
- QNRX vs BPTH Comparison
QNRX vs BPTH Comparison
Compare QNRX & BPTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- BPTH
- Stock Information
- Founded
- QNRX 2018
- BPTH 2007
- Country
- QNRX United States
- BPTH United States
- Employees
- QNRX N/A
- BPTH N/A
- Industry
- QNRX Medical/Dental Instruments
- BPTH Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- BPTH Health Care
- Exchange
- QNRX Nasdaq
- BPTH Nasdaq
- Market Cap
- QNRX 5.3M
- BPTH 2.8M
- IPO Year
- QNRX N/A
- BPTH N/A
- Fundamental
- Price
- QNRX $0.70
- BPTH $1.16
- Analyst Decision
- QNRX Strong Buy
- BPTH Strong Buy
- Analyst Count
- QNRX 1
- BPTH 2
- Target Price
- QNRX $4.00
- BPTH $30.00
- AVG Volume (30 Days)
- QNRX 1.4M
- BPTH 6.2M
- Earning Date
- QNRX 11-07-2024
- BPTH 11-15-2024
- Dividend Yield
- QNRX N/A
- BPTH N/A
- EPS Growth
- QNRX N/A
- BPTH N/A
- EPS
- QNRX N/A
- BPTH N/A
- Revenue
- QNRX N/A
- BPTH N/A
- Revenue This Year
- QNRX N/A
- BPTH N/A
- Revenue Next Year
- QNRX N/A
- BPTH N/A
- P/E Ratio
- QNRX N/A
- BPTH N/A
- Revenue Growth
- QNRX N/A
- BPTH N/A
- 52 Week Low
- QNRX $0.43
- BPTH $0.59
- 52 Week High
- QNRX $6.18
- BPTH $12.00
- Technical
- Relative Strength Index (RSI)
- QNRX 54.60
- BPTH 57.25
- Support Level
- QNRX $0.47
- BPTH $1.11
- Resistance Level
- QNRX $0.75
- BPTH $1.34
- Average True Range (ATR)
- QNRX 0.10
- BPTH 0.30
- MACD
- QNRX 0.01
- BPTH 0.03
- Stochastic Oscillator
- QNRX 71.51
- BPTH 18.91
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About BPTH Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.